Viking Therapeutics
@Viking_VKTX
Followers
3,224
Following
0
Media
2
Statuses
176
Novel therapeutics for metabolic and endocrine disorders
San Diego, CA
Joined October 2015
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#AMAs
• 216623 Tweets
D-10
• 214171 Tweets
RENJUN
• 130932 Tweets
STRAY KIDS BOYBAND LEGACY
• 100162 Tweets
Dodgers
• 99310 Tweets
Halo
• 95455 Tweets
Giants
• 74170 Tweets
Steelers
• 73162 Tweets
Hobi
• 49679 Tweets
49ers
• 44977 Tweets
Cowboys
• 42595 Tweets
斉藤慎二
• 25646 Tweets
書類送検
• 23520 Tweets
斉藤メンバー
• 23291 Tweets
ジャングルポケット
• 23237 Tweets
#ドンキで見つけた
• 15960 Tweets
Mariah
• 15909 Tweets
Bronny
• 14539 Tweets
Profar
• 13694 Tweets
The Next Prince Q8
• 13528 Tweets
Tatis
• 13238 Tweets
#DigitalFasting
• 13217 Tweets
G DE GARIME
• 12029 Tweets
ロケバス
• 11627 Tweets
ダルビッシュ
• 10947 Tweets
Niners
• 10692 Tweets
Viking Therapeutics to ring the opening bell at the Nasdaq stock market on Monday, July 15. CEO Brian Lian to ring bell at Nasdaq MarketSite in Times Square, New York City.
3
8
39
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
5
7
24
Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018
1
6
25
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
1
7
24
Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018
0
6
17
Viking Therapeutics to Present at Biotech Showcase 2019
1
3
17
Viking Therapeutics to Participate in Upcoming Investor Conferences and Events
0
3
16
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
2
1
15
Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA)
1
4
15
Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
4
5
14
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
1
2
14
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
2
2
14
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7
3
14
Viking Therapeutics to Participate in Upcoming Investor Conferences
1
1
12
Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting
2
1
13
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
0
2
11
Viking Therapeutics to Participate in Upcoming Investor Conferences
2
3
11
Viking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018
0
4
9
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
2
2
9
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
1
4
9
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023
0
1
10
Viking Therapeutics Announces Closing of Public Offering of Common Stock
0
1
9
Viking Therapeutics to Participate in Ligand Pharmaceuticals Analyst Day, November 14 in New York City
0
3
9
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
1
1
9
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
1
2
9
Viking Therapeutics to Participate in Upcoming Investor Conferences
1
1
9
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
17
0
9
Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
3
2
9
Viking Therapeutics to Present at 22nd Annual Needham Healthcare Conference
0
1
9
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020
0
4
8
Viking Therapeutics to Participate in Upcoming Investor Conferences
0
4
9
Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference
2
2
7
Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018
0
2
9
Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023
0
0
8
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
1
2
8
Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
1
2
7
Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference
1
2
8
Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
4
1
8
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
0
3
7
Viking Therapeutics to Participate in Upcoming Investor Conferences
1
3
8
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
2
3
7
Viking Announces Top-Line Results from POC Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy
0
1
7
Viking Therapeutics to Present at Upcoming Investor Conferences
0
2
7
Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
1
2
7
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
1
1
7
Viking Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
1
2
7
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022
0
1
7
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
1
2
6
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
3
2
7
Viking Therapeutics to Present at Upcoming Investor Conferences
0
1
6
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
1
1
5
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
0
4
6
Viking Presents Results from POC Study of VK0214 In Vivo Model of X-ALD at the American Thyroid Association Meeting
0
2
6
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
0
1
6
Viking Therapeutics to Present at Biotech Showcase 2018
1
1
5
Viking Therapeutics to Present at Biotech Showcase 2020
0
2
6
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019
0
1
6
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018
1
1
5
Viking to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
0
1
6
Viking Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed NASH at the Annual Meeting of the AASLD
0
3
6
Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020
0
2
6
Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
3
2
6
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
0
1
6
Viking Therapeutics to Report Financial Results for First Quarter 2022 on April 27, 2022
0
2
4
Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
0
2
5
Viking Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis
0
2
5
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
0
1
5
Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
0
2
5
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
0
1
5
Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
3
2
5
Viking Therapeutics to Report Financial Results for Second Quarter 2022 on July 27, 2022
0
2
5
Viking Therapeutics to Participate in Upcoming Investor Conferences
1
2
5
Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
0
1
5
Viking Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
3
2
5
Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK2735, Company's Lead Dual GLP-1/GIP Receptor Agonist
0
1
5
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
1
1
5
Viking Therapeutics Announces Senior Management Team Appointments
0
1
5
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021
0
3
5
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
2
2
5
Viking Therapeutics to Participate in Upcoming Investor Conferences
0
1
5
Viking Therapeutics to Present at William Blair Biotech Focus Conference 2022
0
2
4
Viking Therapeutics to Present at SVB Leerink 11th Annual Global Healthcare Conference
1
1
5
Viking Therapeutics to Participate at Upcoming Investor Conferences
0
2
5
Viking Therapeutics to Present at H.C. Wainwright's 5th Annual NASH Investor Conference
0
2
5
Viking Therapeutics to Report Financial Results for First Quarter 2023 on April 26, 2023
2
1
5
Viking Therapeutics to Participate at Upcoming Investor Conferences
0
1
5
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
1
2
5
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
0
1
4
Viking Therapeutics Presents Phase 1 Data and Ongoing Phase 2 Study of VK5211 at 5th FFN Global Congress 2016
0
1
4
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
0
2
4
Viking Therapeutics to Report Financial Results for Third Quarter 2022 on October 26, 2022
1
2
4
Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
1
2
4
Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018
1
1
4
Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD
0
1
3
Viking Therapeutics to Participate in Upcoming Investor Conferences
0
3
3
Viking Highlights VK5211 and VK2809 Pipeline Programs at Ligand Analyst and Investor Event in New York
0
2
3
Viking Therapeutics to Present at Stifel 2022 Healthcare Conference
2
2
4
Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
0
2
3